Literature DB >> 18342661

Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance.

Jinru Shia1, David S Klimstra, James R Nitzkorski, Philip S Low, Mithat Gonen, Ron Landmann, Martin R Weiser, Wilbur A Franklin, Franklyn G Prendergast, Linda Murphy, Laura H Tang, Larissa Temple, Jose G Guillem, W Douglas Wong, Philip B Paty.   

Abstract

Folate receptor alpha (FRalpha) has emerged as a potential cancer therapy target with several folate-linked therapeutic agents currently undergoing clinical trials. In addition, FRalpha expression in tumors may offer prognostic significance. Most studies on FRalpha expression used reverse transcriptase polymerase chain reaction or cytofluorimetric assays. The applicability of such methods to paraffin-embedded tissues is limited. The aims of this study were to assess the feasibility of immunohistochemistry in detecting FRalpha expression and to assess the patterns and clinical significance of FRalpha expression in colorectal tissues. We used tissue microarrays containing 152 normal colorectal mucosa samples, 42 adenomas, 177 primary, and 52 metastatic colorectal carcinomas. Our results showed that staining for FRalpha on colorectal tissues was simple and easy to read. FRalpha positivity was more frequent in carcinomas (33% in primaries and 44% in metastases) than in normal mucosa or adenoma (7% in both) (P < .001). Positive staining in primary carcinomas correlated with younger age (n = 130) (P = .008), presence of distant metastasis (n = 130) (P = .043), and non-high-frequency microsatellite instability status (as detected by the standard polymerase chain reaction method using the 5 National Cancer Institute-recommended markers) (n = 77) (P = .006). Positive staining in primary carcinomas also correlated with a worse 5-year disease-specific survival (P = .04) on univariate but not multivariate analysis. Thus, our data show that there is selective expression of FRalpha in some colorectal cancers, providing a foundation for investigating the use of folate conjugates for imaging and therapy of colorectal tumors. Furthermore, our results suggest that a possible association exists between FRalpha expression and the microsatellite instability status in colorectal carcinoma. The significance of such an association as well as the prognostic value of FRalpha expression deserves further exploration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342661     DOI: 10.1016/j.humpath.2007.09.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

1.  High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Authors:  Maria Ines Nunez; Carmen Behrens; Denise M Woods; Heather Lin; Milind Suraokar; Humam Kadara; Wayne Hofstetter; Neda Kalhor; J Jack Lee; Wilbur Franklin; David J Stewart; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform.

Authors:  Sergio Sandoval; Natalie Mendez; Jesus G Alfaro; Jian Yang; Sharraya Aschemeyer; Alex Liberman; William C Trogler; Andrew C Kummel
Journal:  J Biomed Opt       Date:  2015-08       Impact factor: 3.170

Review 3.  Basics to advances in nanotherapy of colorectal cancer.

Authors:  Ankita Tiwari; Shivani Saraf; Ankit Jain; Pritish K Panda; Amit Verma; Sanjay K Jain
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 4.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 5.  Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.

Authors:  Ignace Vergote; Christopher P Leamon
Journal:  Ther Adv Med Oncol       Date:  2015-07       Impact factor: 8.168

6.  Folate-PEG-CKK(2)-DTPA, A Potential Carrier for Lymph-Metastasized Tumor Targeting.

Authors:  Bing Gu; Cao Xie; Jianhua Zhu; Wei He; Weiyue Lu
Journal:  Pharm Res       Date:  2010-03-11       Impact factor: 4.200

7.  Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.

Authors:  Marleen van Oosten; Lucia Ma Crane; Joost Bart; Fijs W van Leeuwen; Gooitzen M van Dam
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

8.  Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.

Authors:  Nabil F Saba; Xu Wang; Susan Müller; Mourad Tighiouart; Kwangjae Cho; Shuming Nie; Zhuo Chen; Dong M Shin
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

Review 9.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

10.  Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Authors:  Daniel C Christoph; Bernadette Reyna Asuncion; Biftu Hassan; Cindy Tran; Julia D Maltzman; Daniel J O'Shannessy; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Mathias Hoiczyk; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.